Mirtazapin-Hormosan (Mirtazapine)

Mirtazapine, the active ingredient in Mirtazapin-Hormosan, is a NaSSA (noradrenergic and specific serotonergic antidepressant) presented as an oral tablet for oral use. It treats major depressive disorder in adult patients and is approved in the European Union for this indication.

GNH USA supplies Mirtazapin-Hormosan as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Mirtazapine is indicated for depressive disorders and is used primarily to alleviate symptoms of major depressive illness.

- Major depressive disorder: reduces depressive symptoms and improves overall mood in adult patients. - Depressive episodes with insomnia: helps restore sleep while treating depression. - Depression with anxiety features: alleviates both low mood and associated anxiety in many patients.

Mirtazapine may cause a range of adverse reactions, which are categorized by frequency and severity.

Common Side Effects: - Drowsiness: feeling unusually sleepy, especially after the first weeks of therapy. - Increased appetite: a noticeable rise in hunger leading to weight gain. - Dry mouth: reduced salivation causing oral discomfort. - Constipation: slowed bowel movements. - Dizziness: light‑headed sensation on standing. - Fatigue: general lack of energy.

Serious or Rare Side Effects: - Agranulocytosis: severe drop in white blood cells, requiring immediate medical attention. - Severe hypersensitivity: rash, swelling, or difficulty breathing. - Suicidal thoughts: emergence or worsening of suicidal ideation, especially early in treatment.

Before initiating therapy, clinicians should evaluate individual risk factors and monitor patients regularly.

- Monitor weight: patients may experience increased appetite and weight gain. - Assess liver function: use with caution in hepatic impairment. - Evaluate renal status: dose adjustment may be needed in severe renal dysfunction. - Screen for suicidal ideation: especially during the first weeks of treatment. - Avoid abrupt discontinuation: taper the dose to reduce withdrawal symptoms. - Store at ambient temperature: keep below 25°C in the original packaging, protected from moisture.

Mirtazapine can interact with several drug classes; awareness of interaction severity guides clinical decisions.

Major Interactions (Avoid): - Monoamine oxidase inhibitors (MAOIs): risk of serotonin syndrome; a 14‑day washout is required. - CNS depressants (e.g., benzodiazepines, opioids): may potentiate sedation and respiratory depression.

Moderate Interactions (Monitor Closely): - CYP2D6 inhibitors (e.g., fluoxetine, paroxetine): can increase mirtazapine plasma levels. - Anticholinergic agents: additive dry‑mouth and constipation effects. - Alcohol: may enhance sedative properties and impair cognition.